Colin K. Skepper,Duncan Armstrong,Carl J. Balibar,Daniel Bauer,Cornelia Bellamacina,Bret M. Benton,Dirksen Bussiere,Gianfranco De Pascale,Javier De Vicente,Charles R. Dean,Bhavesh Dhumale,L. Mark Fisher,John Fuller,Mangesh Fulsunder,Lauren M. Holder,Cheng Hu,Bhavin Kantariya,Guillaume Lapointe,Jennifer A. Leeds,Xiaolin Li,Peichao Lu,Anatoli Lvov,Sylvia Ma,Shravanthi Madhavan,Swapnil Malekar,David McKenney,Wosenu Mergo,Louis Metzger,Heinz E. Moser,Daniel Mutnick,Jonas Noeske,Colin Osborne,Ashish Patel,Darshit Patel,Tushar Patel,Krunal Prajapati,Katherine R. Prosen,Folkert Reck,Daryl L. Richie,Alice Rico,Mark R. Sanderson,Shailesh Satasia,William S. Sawyer,Jogitha Selvarajah,Nirav Shah,Kartik Shanghavi,Wei Shu,Katherine V. Thompson,Martin Traebert,Anand Vala,Lakhan Vala,Dennis A. Veselkov,Jason Vo,Michael Wang,Marcella Widya,Sarah L. Williams,Yongjin Xu,Qin Yue,Richard Zang,Bo Zhou,Alexey Rivkin

Abstract:Since their discovery over 5 decades ago, quinolone antibiotics have found enormous success as broad spectrum agents that exert their activity through dual inhibition of bacterial DNA gyrase and topoisomerase IV. Increasing rates of resistance, driven largely by target-based mutations in the GyrA/ParC quinolone resistance determining region, have eroded the utility and threaten the future use of this vital class of antibiotics. Herein we describe the discovery and optimization of a series of 4-(aminomethyl)quinolin-2(1H)-ones, exemplified by 34, that inhibit bacterial DNA gyrase and topoisomerase IV and display potent activity against ciprofloxacin-resistant Gram-negative pathogens. X-ray crystallography reveals that 34 occupies the classical quinolone binding site in the topoisomerase IV-DNA cleavage complex but does not form significant contacts with residues in the quinolone resistance determining region.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00347?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00347</a>.Crystallographic data table for the structure of K. pneumoniae topoisomerase IV bound to compound 34; unbiased electron-density difference map (Fobs – Fcalc) for 34 bound to K. pneumoniae topoisomerase IV; interaction diagram of compound 34 bound to topoisomerase IV from K. pneumoniae; plot of CFU/thigh determined for each dose of compound 34 in the neutropenic murine thigh infection model; SEC chromatograms showing separation of supercoiled and relaxed DNA and detection of decatenated kDNA; LC/MS traces of all final compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00347/suppl_file/jm0c00347_si_001.pdf">PDF</a>)Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00347/suppl_file/jm0c00347_si_002.csv">CSV</a>)This article has not yet been cited by other publications.

Discovery of aminopiperidine based potent & novel topoisomerase inhibitor with broad spectrum anti-bacterial activity

Multi-Targeting Exploration of New 2-Aminothiazolyl Quinolones: Synthesis, Antimicrobial Evaluation, Interaction with Dna, Combination with Topoisomerase Iv and Penetrability into Cells

Discovery of Natural Berberine-Derived Nitroimidazoles As Potentially Multi-Targeting Agents Against Drug-Resistant Escherichia Coli

Novel Potentially Antibacterial Naphthalimide-Derived Metronidazoles: Design, Synthesis, Biological Evaluation and Supramolecular Interactions with DNA, Human Serum Albumin and Topoisomerase II

Design, synthesis, and biological evaluation of novel carbazole aminothiazoles as potential DNA-targeting antimicrobial agents

Novel Bacterial Topoisomerase Inhibitors with Potent Broad-Spectrum Activity against Drug-Resistant Bacteria

Novel Aminopyrimidinyl Benzimidazoles As Potentially Antimicrobial Agents: Design, Synthesis and Biological Evaluation

Discovery of 2-Aminothiazolyl Berberine Derivatives As Effectively Antibacterial Agents Toward Clinically Drug-Resistant Gram-negative Acinetobacter Baumanii.

Discovery of Novel Nitroimidazole Enols As Pseudomonas Aeruginosa DNA Cleavage Agents

Discovery of novel bacterial topoisomerase I inhibitors by use of in silico docking and in vitro assays

The Structural Features of Novel Bacterial Topoisomerase Inhibitors That Define Their Activity on Topoisomerase IV

In-silico driven design and development of spirobenzimidazo-quinazolines as potential DNA gyrase inhibitors

Design, synthesis, molecular docking, and antibacterial activity of novel amide-linked tetrahydrobenzothienopyrimidinone derivatives as potential DNA gyrase and topoisomerase IV inhibitors

Discovery and Optimization of Indolyl-Containing 4-Hydroxy-2-pyridone Type II DNA Topoisomerase Inhibitors Active Against Multidrug Resistant Gram-negative Bacteria

In silico evaluation of usnic acid derivatives to discover potential antibacterial drugs against DNA gyrase B and DNA topoisomerase IV

Discovery of new Schiff bases of the disalicylic acid scaffold as DNA gyrase and topoisomerase IV inhibitors endowed with antibacterial properties

New N-phenylpyrrolamide inhibitors of DNA gyrase with improved antibacterial activity

Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents

Benzothiazole DNA gyrase inhibitors and their conjugates with siderophore mimics: design, synthesis and evaluation

DESIGN, INSILICO SCREENING, MOLECULAR DOCKING, SYNTHESIS AND BIOLOGICAL EVALUATION OF BENZO-FUSED FIVE MEMBERED NITROGEN CONTAINING HETEROCYCLE AGAINST DNA GYRASE SUBUNIT B AS POTENTIAL ANTIMICROBIAL AGENT

Topoisomerase Inhibitors Addressing Fluoroquinolone Resistance in Gram-Negative Bacteria